PowerPoint Presentation


Emerging pharmaceutical company in targeted therapies


OVERVIEW OF 2015 AND PERSPECTIVES FOR 2016

JANUARY 2016


This presentation, together with the material set forth herein, does not constitute an offer of securities for sale nor the solicitation of an offer to purchase securities in any jurisdiction. Distribution of such presentation in certain jurisdiction may constitute a breach of applicable laws and regulation.

Neither the Company, nor any of its advisors and representatives may accept any responsibility for any loss or damage incurred by the use of this document or the information set forth herein. Neither the Company, nor any of its advisors and representatives takes any undertaking nor guarantees, whether explicitly or tacitly, the accuracy or the completeness of the information set forth herein.

In particular, in France, any decision to purchase such securities shall rely solely on the documents that have been reviewed by the Autorité des Marchés Financiers (the "AMF") and published by the Company.

This document does not constitute an offer to purchase any financial instruments in the United States. Securities mentioned in this document have not been and will not be registered under the Securities Act of 1933, as amended (the "Securities Act") and may not be offered or sold in the United States absent registration or an exemption from the registration requirements of the Securities Act. Any public offer of securities in the United States shall be made by means of a prospectus that may be obtained from the Company containing detailed information regarding the Company, its management and financial statements. The Company does not intend to register any offering in all or in part or to make a public offer of securities in the United States.

This document contains information on the objectives of the Company along with some projections. The reader's attention is drawn to the fact that these objectives may not be fulfilled, and the forecasts or information provided may prove erroneous, and the Company is not required to update such information. Past performance is no guide to future performance and persons needing advice should consult an independent financial adviser.


OVERVIEW OF 2015


PERSPECTIVES FOR 2016

CLINICAL DEVELOPMENT OF MASITINIB

Masitinib is a tyrosine kinase inhibitor targeting mast cells and macrophages and developed in thirteen phase 3 indications in oncology, in neurology, and in inflammatory diseases.


Indications with phase 3 on-going with masitinib

Oncology Digestive cancers

GIST L1

GIST L2

Pancreatic cancer

Metastatic colorectal cancer in 2nd line

Oncology - Heamatology

Multiple Myeloma in 2nd Line

Peripheral T-cell lymphoma

Oncology - Hormonal cancer and other cancer

MCR Prostate Cancer in 1st line

Melanoma with Kit JM mutation

CNS disease

Amyotrophic lateral sclerosis

Progressive forms of multiple sclerosis

Alzheimer's diseases

Inflammatory diseases

Severe systemic Mastocytosis

Severe asthma uncontrolled by oral corticosteroids

AB Science SA issued this content on 2016-01-12 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 2016-01-12 14:48:14 UTC

Original Document: http://www.ab-science.com/file_bdd/content/1452609953_ABScience.pdf